Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial

Nature Medicine

Volumn 2, Issue 10, 1996, Pages 1109-1115

  Vandenbark, Arthur A ^a,b   Chou, Yuan K ^b   Whitham, Ruth ^a,b   Mass, Michele ^b   Buenafe, Abigail ^b   Liefeld, Diane ^b   Kavanagh, Daniel ^a   Cooper, Shelley ^b   Hashim, George A ^c   Offner, Halina ^a,b   Bourdette, Dennis N ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Council for Tobacco Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; T LYMPHOCYTE RECEPTOR; VACCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AUTOIMMUNE DISEASES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-10; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; PILOT PROJECTS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS; TH2 CELLS; VACCINES;

EID: 16044361810     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1096-1109     Document Type: Article

References (50)

1. Jerne, N.K. Idiotypic networks and other preconceived ideas. Immunol. Rev. 79, 5-24 (1984).
2. Cohen, I.R. & Young, D.B. Autoimmunity, microbial immunity and the immunological homunculus. Immunol. Today 12, 105-110 (1991).
3. Claverie, J.M., Prochnicka-Chalufour, A. & Bougueleret, A. Implications of a Fab-like structure for the T-cell receptor. Immunol. Today 10, 10-14 (1989).
4. Davis, M.M. & Bjorkman, P.J. T-cell antigen receptor genes and T-cell recognition. Nature 334, 395-402 (1988).
5. Williams, W.V., Weiner, D.B., Wadsworth, S. & Greene, M.I. The antigen-major histocompatibility complex-T-cell receptor interaction: A structural analysis. Immunol. Rev. 7, 339-344 (1988).
6. Vandenbark, A.A., Hashim, G.A. & Offner, H. T cell receptor peptides in treatment of autoimmune disease: Rationale and potential. J. Neurosci. Res. 43, 391-402 (1996).
7. Heber-Katz, E. & Acha-Orbea, H. The V-region disease hypothesis: Evidence from autoimmune encephalomyelitis. Immunol. Today 10, 164-169 (1989).
8. Lider, O., Reshef, T., Beraud, E., Ben-Nun, A. & Cohen, I.R. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 239, 181-183 (1988).
9. Vandenbark, A.A., Hashim, G. & Offner, H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341, 541-544 (1989).
10. Offner, H., Hashim, G.A. & Vandenbark, A.A. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science 251, 430-432 (1991).
11. Howell, M.D. et al. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246, 668-670 (1989).
12. Stevens, D.B., Karpus, W.J., Gould, K.E. & Swanborg, R.H. Studies of Vβ8 T cell receptor peptide treatment in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 37, 123-129 (1991).
13. + T cells in recovery from antigen-induced autoimmune disease. J. Exp. Med. 178, 909-916 (1993).
14. Gregorian, S.K., Lee, W.P., Doudikian, N. & Amento, E.P. Two distinct T cell receptor peptides independently regulate experimental autoimmune neuritis. Am. Assoc. Immunol. 150, 28A (1993).
15. Broeren, C.P.M. et al. CDR1 T-cell receptor β-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions. Proc. Natl. Acad. Sci. USA 91, 5997-6001 (1994).
16. Matsumoto, Y., Tsuchida, M., Hanawa, H. & Abo, T. T cell receptor peptide therapy for autoimmune encephalomyelitis: Stronger immunization is necessary for effective vaccination. Cell. Immunol. 153, 468-478 (1994).
17. Kuhrober, A., Schirmbeck, R. & Reimann, J. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL. Eur. J. Immunol. 24, 1172-1180 (1994).
18. Haqqui, T.M., Qu, X.-M., Ma, J. & Sy, M.S. Immunization with TCR Vβ region peptides completely prevents the induction of collagen induced arthritis. Ninth Int. Cong. Immunol. Abstr. 5014, 845 (1995).
19. Kotzin, B.L. et al. Preferential T cell receptor Vβ gene usage in myelin basic protein reactive T cell clones from patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 88, 9161-9165 (1991).
20. Oksenberg, J.R. et al. Selection of T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362, 68-70 (1993).
21. Shimonkevitz, R., Murray, R. & Kotzin, B. Characterization of T-cell receptor Vβ usage in the brain of a subject with multiple sclerosis. Ann. N. Y. Acad. Sci. 756, 305-306 (1995).
22. Bourdette, D.N. et al. Immunity to T cell receptor peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides. J. Immunol. 152, 2510-2519 (1994).
23. Wucherpfennig, K.W. et al. Shared human T cell receptor Vβ usage to immunodominant regions of myelin basic protein. Science 248, 1016-1019 (1990).
24. Ben-Nun, A. et al. Restricted T-cell receptor Vβ gene usage by myelin basic protein- specific T-cell clones in multiple sclerosis: Predominant genes vary in individuals. Proc. Natl. Acad. Sci. USA 88, 2466-2470 (1991).
25. Vandenbark, A.A., Vainiene, M., Celnik, B., Hashim, G. & Offner, H. TCR peptide therapy decreases the frequency of encephalitogenic T cells in the periphery and the central nervous system. J. Neuroimmunol. 39, 251-260 (1992).
26. Desquenne-Clark, L., Esch, T.R., Otvos, L., Jr., & Heber-Katz, E. T cell receptor peptide immunization leads to enhanced and chronic experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA 88, 7219-7223 (1991).
27. Chou, Y.K. et al. MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR Vβ CDR2 peptides: Comparison with myelin basic protein-specific T cells. J. Neurosci. Res. (in the press).
28. Falcioni, F. et al. Self tolerance to T cell receptor Vβ sequences. J. Exp. Med. 182, 249-254 (1995).
29. Vandenbark, A.A. [Letter to the editor]. J. Immunol. 153, 910 (1994).
30. Sant'Angelo, D.B. et al. The specificity and orientation of a TCR to its peptide-MHC class II ligands. Immunity 4, 367-376 (1996).
31. Voskuhl, R.R. et al. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 15, 137-143 (1993).
32. Chou, Y.K. et al. Immunity to T cell receptor peptides in multiple sclerosis. II. T cell recognition of Vβ5.2and Vβ6.1 CDR2 peptides. J. Immunol. 152, 2520-2529 (1994).
33. Allegretta, M., Nicklas, J.A., Sriram, S. & Albertini, R.J. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247, 718-721 (1990).
34. Vandenbark, A.A. et al. Episodic changes in T cell frequencies to myelin basic protein in patients with multiple sclerosis. Neurology 43, 2416-2417 (1993).
35. Zhang, J. et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179, 973-984 (1994).
36. Weiner, H.L. et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259, 1321-1324 (1993).
37. Zhang, J., Medaer, R., Stinissen, P., Hafler, D.A. & Raus, J.C.M. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261, 1451-1454 (1993).
38. Miller, A., Al-Sabagh, A., Santos, L.M.B., Prabhu-Das, M. & Weiner, H.L. Epitopes of myelin basic protein that trigger TGF-β release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression. J. Immuno. 151, 7307-7315 (1993).
39. + suppressor cells inhibit the function of effector cells of EAE through a mechanism involving transforming growth factor-beta. J. Immunol. 146, 1163-1168 (1991).
40. + T cells. Res. Immunol. 142, 14-22 (1991).
41. Racke, M.K. et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180, 1961-1966 (1994).
42. Kennedy, M.K., Torrance, D.S., Picha, K.S. & Mohler, K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149, 2496-2505 (1992).
43. Rott, O., Fleischer, B. & Cash, E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur. J. Immunol. 24, 1434-1440 (1994).
44. Poser, C.M. et al. New Diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann. Neurol. 13, 227-236 (1983).
45. Diebler, G.E., Boyd, L.F. & Kies, M.W. Enzymatic and nonenzymatic degradation of myelin basic protein. Neurochemistry 9, 1371-1385 (1984).
46. Scharf, S.J., Griffith, R.L. & Erlich, H.A. Rapid typing of DNA sequence polymorphism at the HLA-DRB1 locus using the polymerase chain reaction and nonradioactive probes. Hum. Immunol. 30, 190-201 (1991).
47. Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 26, 1614-1619 (1981).
48. Kurtzke, J.F. Further notes on disability evaluation in multiple sclerosis with scale modification. Neurology 15, 654-662 (1965).
49. Hauser, S.L., Dawson, D.M. & Lehrich, J. C. Intensive immunosuppression in progressive multiple sclerosis: A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308, 173-180 (1983).
50. Goodkin, D.E. et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 37, 30-40 (1995).